Aging is no longer seen as an inevitable process but rather a biological mechanism that can be slowed—or even reversed. Clock.bio, a longevity-focused biotech startup, is using cellular reprogramming and senescence reversal to combat aging at its root cause (GenomeWeb, 2025).
Clock.bio has developed a CRISPR-based screening method combined with single-cell RNA sequencing to identify genes involved in aging. Their aging cell database contains over 100 gene targets, which could unlock novel rejuvenation therapies (GenomeWeb, 2025).
In a major step forward, Clock.bio raised $5.3 million in seed funding to advance its research. Investors are increasingly backing longevity biotech, seeing it as a market poised for exponential growth (GenomeWeb, 2025).
By targeting cellular mechanisms of aging, Clock.bio aims to extend human healthspan, delaying the onset of age-related diseases. If successful, their work could revolutionize medicine, moving healthcare from disease treatment to prevention.
Sources: GenomeWeb
Helping biotech startups and professionals scale smarter with the right match.